{"organizations": [], "uuid": "1fcd7042ae5c313982f6c396d586c621fc858500", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-provides-fy-2/brief-sarepta-therapeutics-provides-fy-2018-rev-forecast-for-exondys-51-idUSASB0C07Y", "country": "US", "domain_rank": 408, "title": "BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T20:49:00.000+02:00", "replies_count": 0, "uuid": "1fcd7042ae5c313982f6c396d586c621fc858500"}, "author": "", "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-provides-fy-2/brief-sarepta-therapeutics-provides-fy-2018-rev-forecast-for-exondys-51-idUSASB0C07Y", "ord_in_thread": 0, "title": "BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-sarepta therapeutics", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "exondys", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sarepta therapeutics inc", "sentiment": "none"}, {"name": "exondys", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 8, 2018 / 6:50 PM / Updated 21 minutes ago BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51 Reuters Staff 1 Min Read \nJan 8 (Reuters) - Sarepta Therapeutics Inc: \n* SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH \n* Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION * SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION \n* SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION \n* SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-08T20:49:00.000+02:00", "crawled": "2018-01-08T21:16:50.004+02:00", "highlightTitle": ""}